Formulation & Delivery Of Spray Dried Biologics For Nasal Dosage Forms

Interest in nasal delivery of biologics is accelerating as developers seek alternatives to injectable dosage forms and cold‑chain‑dependent liquids. Spray drying has emerged as a practical approach for converting sensitive biologics into stable dry powders while preserving structure and biological activity. By rapidly removing water under controlled conditions, the process minimizes thermal stress and improves long‑term stability.

Particle engineering plays a central role, allowing control over size and aerodynamic properties to achieve targeted nasal deposition while limiting unwanted lung exposure. Careful selection of excipients, spray‑drying parameters, and delivery devices enables formulation of peptides, proteins, vaccines, and nucleic‑acid‑based therapies for different regions of the nasal anatomy, including systemic, immune, and direct‑to‑brain targets.

Equally important is analytical testing to confirm retained structure, activity, and deposition behavior. Together, formulation design, device compatibility, and aerodynamic assessment help de‑risk development and support scalable manufacturing of nasal biologic products, creating a viable pathway from early research through clinical advancement.